EUVIMEDEUVIMED entdecken
Crossref

Equine Metabolism of Voxelotor and Its Impact on Hematological Indices: A Doping Control Perspective

Abdul Khader Karakka Kal iD, Michael Benedict Subhahar, Moses Philip, Fatma Mohammed Graiban, Tajudheen K Karatt iD, Binoy Mathew, Ringu Mareena George, Balakrishnan Maruthasalam

Drug Testing and Analysis · 2025

DOI: 10.1002/dta.3957 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Testing and Analysis, 2025. Verfasst von Abdul Khader Karakka Kal und 7 weiteren Autor:innen. Beteiligte Einrichtung: Equine Forensic Unit, Central Veterinary Research Laboratory, Dubai, UAE. Hauptthemen laut MEDLINE: Pyrazoles, Pyrazines. Die Arbeit nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Voxelotor, a therapeutic drug for sickle cell disease, has been reported to elevate serum erythropoietin and hemoglobin levels in healthy individuals. Because of its potential to alter blood parameters, the World Anti‐Doping Agency (WADA) classified voxelotor under category M1 of the 2023 Prohibited List. Despite this classification, little is known about its metabolic behavior in either humans or animals. In this study, the metabolism of voxelotor was investigated in Thoroughbred horses after oral administration. Using liquid chromatography high‐resolution mass spectrometry (LC‐HRMS), 35 metabolites were detected. Among them, the most prominent pathways included hydroxylation and reductive transformations (Phase I), as well as glucuronidation and sulfonation (Phase II). Notably, several glucuronide conjugates and hydroxylated derivatives were identified as major metabolites, with extended detection times that make them particularly relevant for antidoping surveillance. Blood analyses also revealed changes in red blood cell count, hemoglobin concentration, packed cell volume, and platelet levels. Together, these findings provide practical insight into voxelotor's metabolic profile in equines and highlight specific metabolites useful for doping control. Further studies are needed to better define its hematological impact and to confirm whether the observed clinical effects are drug related.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrazolesPyrazinesHorsesAnimalsDoping in SportsSubstance Abuse DetectionHemoglobinsChromatography, LiquidMaleErythrocyte CountTandem Mass SpectrometryAdministration, Oral

Stichwörter der Autor:innen

GBT440hemoglobin S polymerization inhibitorin vivometabolite characterizationvoxelotor

Substanzen

HemoglobinsPyrazolesPyrazines

Autor:innen und Institutionen

  • Equine Forensic Unit, Central Veterinary Research Laboratory, Dubai, UAE.
  • Haematology and Biochemistry, Central Veterinary Research Laboratory, Dubai, UAE.

ORCID-Profile: Abdul Khader Karakka Kal, Tajudheen K Karatt

Zitieren

APA

Kal, A. K. K., Subhahar, M. B., Philip, M., Graiban, F. M., Karatt, T. K., Mathew, B., George, R. M., & Maruthasalam, B. (2025). Equine Metabolism of Voxelotor and Its Impact on Hematological Indices: A Doping Control Perspective. Drug Testing and Analysis. https://doi.org/10.1002/dta.3957

Vancouver

Kal AKK, Subhahar MB, Philip M, Graiban FM, Karatt TK, Mathew B, et al. Equine Metabolism of Voxelotor and Its Impact on Hematological Indices: A Doping Control Perspective. Drug Testing and Analysis. 2025. doi:10.1002/dta.3957

BibTeX
@article{Kal2025,
  author = {Kal, Abdul Khader Karakka and Subhahar, Michael Benedict and Philip, Moses and Graiban, Fatma Mohammed and Karatt, Tajudheen K and Mathew, Binoy and George, Ringu Mareena and Maruthasalam, Balakrishnan},
  title = {Equine Metabolism of Voxelotor and Its Impact on Hematological Indices: A Doping Control Perspective},
  journal = {Drug Testing and Analysis},
  year = {2025},
  doi = {10.1002/dta.3957}
}
Kostenlos starten →